ALXN Alexion Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 10 December 2019 François Nader, M.D., Joins Moderna's Board of Directors

   Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

2. 06 December 2019 Alexion Issues Statement on Path to Value Creation

   Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and management team are focused on delivering long-term

3. 26 November 2019 Alexion to Present at the 2019 Evercore ISI HealthCONx

   Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation

4. 22 November 2019 SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

   - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving

5. 13 November 2019 Alexion to Present at the 2019 Stifel Healthcare Conference

   Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET. An audio webcast of the

6. 12 November 2019 Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

   NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

7. 07 November 2019 Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

   – Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2

8. 06 November 2019 Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting

   - Accepted abstracts include presentations of ULTOMIRIS® (ravulizumab-cwvz) Phase 3 PNH data through 52 weeks - - ULTOMIRIS is the first and only long-acting C5 complement inhibitor, now available in the U.S. for the

9. 18 October 2019 Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)

   - At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food

10. 10 October 2019 Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer

    - Dr. Carino to head up newly integrated Corporate Affairs function including global government affairs, public policy and communications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of

11. 10 October 2019 Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

    - Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive

12. 08 October 2019 Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following

13. 17 September 2019 Alexion Announces CFO Succession

    - Aradhana Sarin, M.D., to become CFO after filing of Q3 2019 results - - Paul Clancy to step down as CFO and serve as senior advisor through mid-2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced

14. 09 September 2019 Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

    - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to

15. 04 September 2019 Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m. ET. An

16. 28 August 2019 Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

    - Five abstracts accepted, including new long-term data from PREVENT trial of SOLIRIS® (eculizumab) in adults with anti-AQP4 antibody-positive NMOSD - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that

17. 28 August 2019 Alexion to Present at the 14th Annual Citi Biotech Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET. An audio webcast of the

18. 27 August 2019 European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)

     - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%

19. 27 August 2019 European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)

     - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%